Home
    Disclaimer
    ← Back to Proscaline
    Proscaline molecular structure

    Proscaline Stats & Data

    Psychedelic Stimulant Research-chemical
    P 4-propoxy-3,5-dmpea
    NPS DataHub
    MW240.32
    FormulaC13H22NO3
    CAS39201-78-0
    IUPAChydrogen 2-(3,5-dimethoxy-4-propoxyphenyl)ethan-1-amine
    SMILESCCCOc1c(OC)cc(CCN)cc1OC.[H+]
    InChIKeyHYWLMSUAZVDUFW-UHFFFAOYSA-O
    Phenethylamines; 2020/1. Von 2-Phenethylamin abgeleitete Verbindungen; 2021/1. Von 2-Phenethylamin abgeleitete Verbindungen; 2022/1. Von 2-Phenethylamin abgeleitete Verbindungen
    Chemical Class Phenethylamine
    Psychoactive Class Psychedelic / Stimulant

    Receptor Profile

    Receptor Actions

    Agonists
    5-HT2A receptor agonist (partial)
    5-HT2B receptor agonist (partial)
    5-HT2C receptor agonist (partial, higher potency than 5-HT2A/2B)

    History & Culture

    Proscaline was first synthesized and investigated by Czech chemist Otakar Leminger in 1972. The compound was subsequently synthesized by David E. Nichols, who published his work in the Journal of Medicinal Chemistry in 1977. Around this period, Alexander Shulgin independently explored the substance, evaluating its effects at doses up to 60 milligrams and estimating its potency to be approximately five times greater than that of mescaline. Shulgin later documented his findings on proscaline in his 1991 book PiHKAL (Phenethylamines I Have Known and Loved), which served as the primary reference for the compound's subjective effects for many years. Despite this early documentation, proscaline remained largely obscure until it appeared for sale on the online research chemical market during the 2010s. The substance was first identified as a novel designer drug in Europe in 2013.

    Effect Profile

    Curated + 8 Reports
    Psychedelic 6.5

    Strong visuals with moderate headspace and body load

    Visual Intensity×3
    10
    Headspace Depth×3
    6
    Auditory Effects×1
    0
    Body Load / Somatic Effects×1
    6
    Stimulant 4.6

    Moderate euphoria with mild stimulation and anxiety/jitters, low focus

    Stimulation / Energy×3
    5
    Euphoria / Mood Lift×2
    6
    Focus / Productivity×2
    2
    Anxiety / Jitters×1
    4
    Based on reports from:
    PiHKAL PiHKAL #140: P Erowid Experience Reports PsychonautWiki Proscaline

    Tolerance & Pharmacokinetics

    drugs.wiki

    Tolerance Decay

    Full tolerance 1d Half tolerance 21d Baseline ~35d

    Experience Report Analysis

    Erowid
    8 Reports
    2016–2021 Date Range
    5 With Age Data
    12 Effects Detected

    Demographics

    Gender Distribution

    Age Distribution

    Reports Over Time

    Effect Analysis

    Erowid

    Effects aggregated from 8 experience reports (8 Erowid)

    8 Reports
    12 Effects Detected
    6 Positive
    5 Adverse
    1 Neutral

    Effect Sentiment Distribution

    Confidence Distribution

    Positive Effects 6

    Color Enhancement 50.0% 70%
    Focus Enhancement 50.0% 70%
    Euphoria 50.0% 70%
    Music Enhancement 37.5% 70%
    Body High 37.5% 70%
    Tactile Enhancement 37.5% 70%

    Adverse Effects 5

    Nausea 50.0% 70%
    Sweating 37.5% 70%
    Muscle Tension 37.5% 70%
    Anxiety 37.5% 70%
    Confusion 37.5% 70%

    Real-World Dose Distribution

    62K Doses

    From 11 individual dose entries

    Oral (n=9)

    Median: 30.0mg 25th: 20.0mg 75th: 50.0mg 90th: 104.0mg
    mg/kg median: 0.329 mg/kg 75th: 0.817

    Form / Preparation

    Most common forms and preparations reported

    Read full reports on Erowid →

    Legal Status

    Country Status Notes
    Germany Controlled (NpSG) Regulated under the Neue-psychoaktive-Stoffe-Gesetz (New Psychoactive Substances Act) since November 26, 2016. Production, import with intent to distribute, administration to others, and trading are criminal offenses. Possession itself is prohibited but not subject to criminal penalty, though ordering may be prosecuted as incitement to market the substance.
    Switzerland Controlled (Verzeichnis E) Classified as a controlled substance under Verzeichnis E, point 130, as a defined derivative of phenethylamine. Exemptions exist for scientific research and industrial applications.
    United Kingdom Class A Controlled as a Class A substance under the Misuse of Drugs Act 1971 via the phenethylamine derivatives catch-all clause. Class A substances carry the most severe penalties under UK law.
    United States Unscheduled Not specifically scheduled under the Controlled Substances Act. However, sale for human consumption could potentially trigger prosecution under the Federal Analogue Act due to structural similarity to mescaline, a Schedule I substance.

    References

    Data Sources

    Cited References

    ← Back to Proscaline